Jin Zhang M.D., Ph.D is editor at The Pharmaceutical Consultant.

Jin Zhang M.D., Ph.D

Articles

Both foreign and domestic pharmas are in a race to bring PD-1/PD-L1 inhibitors into China, writes Jin Zhang.

Jin Zhang outlines how Chinese companies are advancing in the urgent effort to combat stomach cancer.

Jin Zhang provides an overview of China's major bispecific antibody developers.

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.